Jeans M. Santana

Jeans M. Santana

Auto-generated profile, based on publicly available information

Jeans M. Santana

From the Vascular Biology and Therapeutics Program (T.H., T.I., H.H., K.Y., H.B., J.M.S., A.K., G.K., T.R.F., J.J.H., B.A.Y., W.C.S., A.D.), Yale School of Medicine, New Haven, CT

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Seminars in Vascular Surgery
Verified
Journal Article
Open access
HHHaidi Hu
Haidi Hu
SPSandeep Patel
Sandeep Patel
JHJesse J. Hanisch
Jesse J. Hanisch
JSJeans M. Santana
Jeans M. Santana
THTakuya Hashimoto
Takuya Hashimoto
ADAlan Dardik
Alan Dardik
With the increasing prevalence of end-stage renal disease, there is a growing need for hemodialysis. Arteriovenous fistulae (AVF) are the preferred type of vascular access for hemodialysis, but maturation and failure continue to present significant barriers to successful fistula use. AVF maturation integrates outward remodeling with vessel wall thickening in response to drastic hemodynamic changes in the setting of uremia, systemic inflammation, oxidative stress, and pre-existent vascular pathology. AVF can fail due to both failure to mature adequately to support hemodialysis and development of neointimal hyperplasia that narrows the AVF lumen, typically near the fistula anastomosis. Failure due to neointimal hyperplasia involves vascular cell activation and migration and extracellular matrix remodeling with complex interactions of growth factors, adhesion molecules, inflammatory mediators, and chemokines, all of which result in maladaptive remodeling. Different strategies have been proposed to prevent and treat AVF failure based on current understanding of the modes and pathology of access failure; these approaches range from appropriate patient selection and use of alternative surgical strategies for fistula creation, to the use of novel interventional techniques or drugs to treat failing fistulae. Effective treatments to prevent or treat AVF failure require a multidisciplinary approach involving nephrologists, vascular surgeons, and interventional radiologists, careful patient selection, and the use of tailored systemic or localized interventions to improve patient-specific outcomes. This review provides contemporary information on the underlying mechanisms of AVF maturation and failure and discusses the broad spectrum of options that can be tailored for specific therapy.

1 June 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ALAmelia K. Luciano
Amelia K. Luciano
WZWenping Zhou
Wenping Zhou
JSJeans M. Santana
Jeans M. Santana
CKCleo Kyriakides
Cleo Kyriakides
HVHeino Velazquez
Heino Velazquez
WSWilliam C. Sessa
William C. Sessa
Circadian locomotor output cycles kaput (CLOCK) is a transcription factor that activates transcription of clock-controlled genes by heterodimerizing with BMAL1 and binding to E-box elements on DNA. Although several phosphorylation sites on CLOCK have already been identified, this study characterizes a novel phosphorylation site at serine 845 (Ser-836 in humans). Here, we show that CLOCK is a novel AKT substrate in vitro and in cells, and this phosphorylation site is a negative regulator of CLOCK nuclear localization by acting as a binding site for 14-3-3 proteins. To examine the role of CLOCK phosphorylation in vivo, ClockS845A knockin mice were generated using CRISPR/Cas9 technology. ClockS845A mice are essentially normal with normal central circadian rhythms and hemodynamics. However, examination of core circadian gene expression from peripheral tissues demonstrated that ClockS845A mice have diminished expression of Per2, Reverba, Dbp, and Npas2 in skeletal muscle and Per2, Reverba, Dbp, Per1, Rora, and Npas2 in the liver during the circadian cycle. The reduction in Dbp levels is associated with reduced H3K9ac at E-boxes where CLOCK binds despite no change in total CLOCK levels. Thus, CLOCK phosphorylation by AKT on Ser-845 regulates its nuclear translocation and the expression levels of certain core circadian genes in insulin-sensitive tissues.

13 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CPClinton D. Protack
Clinton D. Protack
TFTrenton R. Foster
Trenton R. Foster
THTakuya Hashimoto
Takuya Hashimoto
KYKota Yamamoto
Kota Yamamoto
MLMonica Y. Lee
Monica Y. Lee
ADAlan Dardik
Alan Dardik
Low rates of arteriovenous fistula (AVF) maturation prevent optimal fistula use for hemodialysis; however, the mechanism of venous remodeling in the fistula environment is not well understood. We hypothesized that the embryonic venous determinant Eph-B4 mediates AVF maturation. In human AVF and a mouse aortocaval fistula model, Eph-B4 protein expression increased in the fistula vein; expression of the arterial determinant Ephrin-B2 also increased. Stimulation of Eph-B-mediated signaling with Ephrin-B2/Fc showed improved fistula patency with less wall thickness. Mutagenesis studies showed that tyrosine-774 is critical for Eph-B4 signaling and administration of inactive Eph-B4-Y774F increased fistula wall thickness. Akt1 expression also increased in AVF; Akt1 knockout mice showed reduced fistula diameter and wall thickness. In Akt1 knockout mice, stimulation of Eph-B signaling with Ephrin-B2/Fc showed no effect on remodeling. These results show that AVF maturation is associated with acquisition of dual arteriovenous identity; increased Eph-B activity improves AVF patency. Inhibition of Akt1 function abolishes Eph-B-mediated venous remodeling suggesting that Eph-B4 regulates AVF venous adaptation through an Akt1-mediated mechanism.

1 November 2009 in Journal of Adolescent Health
Verified
Journal Article
Closed access
JAJennifer D. Allen
Jennifer D. Allen
HFHeidi Collins Fantasia
Heidi Collins Fantasia
HFHolly B. Fontenot
Holly B. Fontenot
SFStephen Flaherty
Stephen Flaherty
JSJeans Santana
Jeans Santana

28 June 2016 in Physiological Reports
Verified
Journal Article
Open access
PDF file
HBHualong Bai
Hualong Bai
MWMo Wang
Mo Wang
TFTrenton R. Foster
Trenton R. Foster
HHHaidi Hu
Haidi Hu
HHHao He
Hao He
ADAlan Dardik
Alan Dardik
Pericardial patches are commonly used during cardiovascular surgery to close blood vessels. In arteries, patches accumulate arterial progenitor cells; we hypothesized that venous patches would accumulate venous progenitor cells, in the absence of arterial pressure. We developed a novel rat inferior vena cava (IVC) venotomy model and repaired it with a pericardial patch. Cells infiltrated the patch to form a thick neointima by day 7; some cells were CD34+/VEGFR2+ and CD31+/Eph‐B4+ consistent with development of venous identity in the healing patch. Compared to arterial patches, the venous patches had increased neointimal thickness at day 7 without any pseudoaneurysms. Addition of an arteriovenous fistula (AVF) to increase blood flow on the patch resulted in reduced patch neointimal thickness and proliferation, but neointimal thickness was not reversible with AVF ligation. These results show that rat patch venoplasty is a novel model of aggressive venous neointimal hyperplasia.

1 April 2019 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
THTakuya Hashimoto
Takuya Hashimoto
TIToshihiko Isaji
Toshihiko Isaji
HHHaidi Hu
Haidi Hu
KYKota Yamamoto
Kota Yamamoto
HBHualong Bai
Hualong Bai
ADAlan Dardik
Alan Dardik
Objective—: Arteriovenous fistulae (AVF) are the most common access created for hemodialysis; however, many AVF fail to mature and require repeated intervention, suggesting a need to improve AVF maturation. Eph-B4 (ephrin type-B receptor 4) is the embryonic venous determinant that is functional in adult veins and can regulate AVF maturation. Cav-1 (caveolin-1) is the major scaffolding protein of caveolae—a distinct microdomain that serves as a mechanosensor at the endothelial cell membrane. We hypothesized that Cav-1 function is critical for Eph-B4–mediated AVF maturation. Approach and Results—: In a mouse aortocaval fistula model, both Cav-1 mRNA and protein were increased in the AVF compared with control veins. Cav-1 KO (knockout) mice showed increased fistula wall thickening ( P =0.0005) and outward remodeling ( P <0.0001), with increased eNOS (endothelial NO synthase) activity compared with WT (wild type) mice. Ephrin-B2/Fc inhibited AVF outward remodeling in WT mice but not in Cav-1 KO mice and was maintained in Cav-1 RC (Cav-1 endothelial reconstituted) mice (WT, P =0.0001; Cav-1 KO, P =0.7552; Cav-1 RC, P =0.0002). Cavtratin—a Cav-1 scaffolding domain peptide—decreased AVF wall thickness in WT mice and in Eph-B4 het mice compared with vehicle alone (WT, P =0.0235; Eph-B4 het, P =0.0431); cavtratin also increased AVF patency (day 42) in WT mice ( P =0.0275). Conclusions—: Endothelial Cav-1 mediates Eph-B4–mediated AVF maturation. The Eph-B4-Cav-1 axis regulates adaptive remodeling during venous adaptation to the fistula environment. Manipulation of Cav-1 function may be a translational strategy to enhance AVF patency.